ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment
Anders Lundin(AstraZeneca (Sweden)), Marcello Maresca(AstraZeneca (Australia))
Cited by 3
Related Papers
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing
|Nature Communications|2023|116
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
|Nature Communications|2020|99